From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

British protocol allows insulin-treated pilots to fly safely
MDedge Internal Medicine
Dapagliflozin’s CKD performance sends heart failure messages
MDedge Internal Medicine
Time to screen for liver disease in type 2 diabetes?
MDedge Internal Medicine
PPIs associated with diabetes risk, but questions remain
MDedge Internal Medicine
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Internal Medicine
Empagliflozin cut PA pressures in heart failure patients
MDedge Internal Medicine
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Internal Medicine
Entresto halves renal events in preserved EF heart failure patients
MDedge Internal Medicine
Substance in tears could be used for diabetes monitoring
MDedge Internal Medicine
Recall widens for diabetes drug metformin
MDedge Internal Medicine